help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arai, Y.
Right arrow Articles by Tsutsui, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arai, Y.
Right arrow Articles by Tsutsui, Y.
(American Journal of Pathology. 2003;163:643-652.)
© 2003 American Society for Investigative Pathology

Neuron-Specific Activation of Murine Cytomegalovirus Early Gene e1 Promoter in Transgenic Mice

Yoshifumi Arai*, Mizuho Ishiwata*{dagger}, Satoshi Baba*, Hideya Kawasaki*, Isao Kosugi*, Ren-Yong Li*, Takashi Tsuchida*, Katsutoshi Miura* and Yoshihiro Tsutsui*

From the Department of Pathology,* Hamamatsu University School of Medicine, Hamamatsu; and the Department of Obstetrics and Gynecology,{dagger} University of Tokyo Graduate School of Medicine, Tokyo, Japan


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
The brain is the main target in congenital cytomegalovirus (CMV) infection and immunocompromised patients. No definite evidence that a CMV has special affinity for the central nervous system (CNS) has been published. Here, we generated transgenic mice with an e1 promoter/enhancer region connected to the reporter gene lacZ. Surprisingly, expression of the transgene was completely restricted to the CNS in all lines of transgenic mice. The transgene was expressed in subpopulation of neurons in the cerebral cortex, hippocampus, diencephalon, brainstem, cerebellum, and spinal cord in all of the lines. Non-neuronal cells in the CNS were negative for transgene expression. Activation of the transgene was first observed in neurons of mesencephalon in late gestation, and then the number of positive neurons increased in various parts of the brain as development proceeded. Upon infection of the transgenic mouse brains with MCMV, the location of the activated neurons became more extensive, and the number of such neurons increased. These results suggest that there are host factor(s) that directly activate the MCMV early gene promoter in neurons. This neuron-specific activation may be associated with persistent infection in the brain and may be responsible for the neuronal dysfunction and neuronal cell loss caused by CMV infection.

Human cytomegalovirus (HCMV) is the most significant infectious cause of severe neuronal disorders of the central nervous system (CNS) due to intrauterine infection in humans.1 It is estimated that approximately 5 to 10% of infected infants have generalized inclusion disease at birth, with symptoms such as microcephaly, periventicular calcification, and microphthalmia.2-4 Brain disorders such as mental retardation, sensorineural hearing loss, visual disorder, seizures, and epilepsy have also been reported after subclinical congenital HCMV infection.5,6 In healthy individuals, infection with HCMV is usually asymptomatic, but the virus can cause severe or fatal disease in immunocompromised patients.7 HCMV has become the most frequent opportunistic brain infection in acquired immunodeficiency syndrome (AIDS), resulting in HCMV encephalitis/encephalopathy.8-10 Although the brain is the main target for HCMV infection, the pathogenesis of the brain disorders after long-term infection has not been elucidated because of the limitations in studying human subjects.

Murine cytomegalovirus (MCMV) has been used as a model of human CMV infection with respect to pathogenesis, tissue tropism, persistent infection, and latency.11-13 Similarly to the gene of HCMV and other herpesviruses, MCMV genes are expressed in three sequential phases: immediate-early (IE), early, and late.14 In brains infected with CMV, infected cells consist preferentially of glial cells in the periventricular regions in both HCMV infection2,15 and in mouse models.16,17 These infected cells underwent lytic infection due to strong expression of the IE antigen and late antigen as the viral DNA increased.16 In accordance with these results, the MCMV IE gene-promoter directed glial-specific expression in the transgenic mice.18,19

In chronic infection, the early nuclear antigen tends to be retained in neurons for a prolonged time after infection.20 Previously we made a monoclonal antibody specific for the viral early nuclear antigen,21 which is the product of MCMV early gene e1 (M112–113),22 corresponding to HCMV early gene (UL112–113) from which nuclear DNA-binding phosphoprotein is expressed.23 The neuron-specific expression of the early gene in the chronic infection of the developing mouse brain may be associated with the pathogenesis of brain disorders such as neuronal cell loss or neuronal dysfunction after long-term infection with CMV in the brain.

In the present study, we showed that there is neuron-specific activation of the enhancer/promoter of the MCMV early e1 gene in transgenic mice. This activation can be enhanced by infection with MCMV in the brain. This model may be useful for elucidating mechanisms of the neuron-specific gene expression and for studying the pathogenesis of persistent CMV infection and neuronal dysfunction of the brain.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Construction and Preparation of Transgene

The e1 gene region, including the coding region and the promoter sequence, of MCMV (Smith strain) was reported to be restricted to a region between map units 0.709 and 0.721 of the genome in the HindIII F fragment.24 A plasmid containing the F fragment from the MCMV HindIII library was selected using polymerase chain reaction (PCR) with primers (5' primer, 5'-CGGGGTACCCGAGGAGCGCCACTAGGTTG-3', 3' primer, 5'-ATAGAAGCTTTGGTCTGCTAAATGCGAAGATCG-3') specific for the e1-promoter region. Both primer sequences were obtained from the GenBank database (Accession No. L07320) using Primer3 software. After selection of the F-fragment-containing plasmid, the MCMV-e1-promoter DNA fragment (1572 bp; - 1534 to + 38) was excised and blunt-ended by treatment with Klenow enzyme (TaKaRa, Tokyo, Japan). Then the blunt-ended fragment was ligated into the SmaI-digested pnlacF plasmid. The pnlacF plasmid containing the nuclear localization signal from SV40, the Escherichia coli ß-galactosidase (ß-gal) coding sequence, and the poly(A) tract and an intron from the mouse protamine gene, was provided by Dr. R. D. Palmiter of the University of Washington.25 The resulting plasmid was designated pMCMV-e1-pro-lacZ. The transgene fragment (5.2 kb) used for microinjection was isolated from the plasmid DNA digested with KpnI and BglII.

Generation of Transgenic Mice

Transgenic mice were produced by standard techniques.26 Purified linearized DNA was injected into the pronuclei of fertilized ova derived from BDF1 (C57BL/6 female x DBA/2 male) mice. After injection, ova were transferred to oviducts of pseudopregnant female ICR mice. Transgenic founders were identified by PCR of genomic DNA prepared from tail tips using standard procedures. PCR was performed with MCMV-e1-pro-lacZ-specific primers as described above for 35 cycles of 1 minute at 94°, 1 minute at 60°, and 1 minute at 72°. The reaction products were electrophoresed on a 2.0% agarose gel that was then stained with ethidium bromide and photographed.

Southern Blot Analysis

Transgenic founders identified by PCR were further analyzed by Southern blotting. The genomic DNA and control DNA digested with BamHI, which cuts twice in the lacZ region of the transgene, were electrophoresed on 0.9% agarose gels and transferred onto nylon membranes (MSI, Westborough, MA). The membranes were then probed using a 33P-labeled transgene BamHI fragment and analyzed with Bio Imaging Analyzer (BAS1000Mac, FUJIX, Tokyo, Japan). Founder lines were established from transgenic mice that transmitted MCMV-e1-pro-lacZ to their progeny.

X-Gal Histochemical Staining

Expression analysis was performed on F1 or F2 mice obtained by mating hemizygous transgenic animals with outbred C57BL/6 mice. The mice were anesthetized with diethyl ether and perfused with 4% paraformaldehyde (PFA) in 0.1 mol/L phosphate buffer (PB). After perfusion, tissues were removed and fixed in freshly prepared 4% PFA in 0.1 mol/L PB for 20 minutes at room temperature. The organs and tissues were incubated in a reaction mixture containing 1 mg of 5-bromo-4-chloro-3-indolyl-ß-galactosidase (X-Gal) per ml, 5 mmol/L K4Fe(CN)6, 5 mmol/L K3Fe(CN)6 in 0.1 mol/L PB (pH 7.3) overnight at room temperature.25 After staining, each tissue was embedded in paraffin and sectioned.

LightCycler RT-PCR for Quantification of ß-Galactosidase mRNA

RNA, which was extracted from each freshly removed transgenic mouse’s tissue using RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol, was treated with RNase-free DNaseI (TaKaRa, Otsu, Japan) and reverse-transcribed into cDNA using Superscript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, California). Each sample cDNA was amplified PCR using primers specific to the ß-gal and mouse hypoxanthine guanine phosphoribosyl transferase (HPRT), those sequences are as follows (GenBank): ß-gal, 5'-GCGAATACCTGTTCCGTCAT-3' and 5'-ACATCCAGAGGCACTTCACC-3' for a 97-bp fragment; mouse HPRT, 5'-TGCTCGAGATGTCATGAAGG-3' and 5'-TGTAATCCAGCAGGTCAGCA-3' for 98-bp fragment. LightCycler RT-PCR was performed as described by Schaade et al.27 An aliquot of 2 µl of the extracted cDNA was added to 18 µl of reaction mixture containing 2 mmol/L MgCl2, 0.5 µmol/L concentration of each primer for the ß-galactosidase and mouse HPRT and 2 µl of LightCycler-FastStart DNA Master SYBER Green I (Roche Biochemicals, Mannheim, Germany), respectively. The amount of mRNAs was quantified by a LightCycler (Roche). The experimental PCR protocol was as follows: an initial 10 minutes at 95° for FirstStart TaqDNA polymerase activation, followed by 40 cycles of 15 seconds denaturation at 95°, 5 seconds annealing at 55°, and 10 seconds extension at 72°. Each melting temperature of the specific probes was as follows: ß-gal, 83.6°; mouse HPRT, 84.1°, respectively.

Quantification of ß-gal cDNA and mouse HPRT cDNA was performed with eight 10-fold serial dilutions of each pre-treated PCR products, those DNA concentrations were measured by spectrophotometry at 260 nm and adjusted the copy numbers by PCR grade water dilution. The copy numbers of ß-gal cDNA from organs were expressed as divided by those of mouse HPRT cDNA for normalization. The same samples were also subjected to ordinary PCR using the same primers as shown above, and the PCR products were electrophoresed on 2% agarose gel.

Immunohistochemical Analysis

For immunohistochemical analysis,16 mice from embryonic to adult stages were anesthetized and perfused with 4% PFA in 0.1 mol/L PB. Tissues were removed, fixed with 4% PFA in 0.1 mol/L PB again for 5 to 7 days, embedded in paraffin, and sectioned. For the developmental analysis, mice at embryonic day 18.5 (E18.5), postnatal day 3 (P3), P7, and P28 were processed in the same way. After deparaffinization and rehydration, sections were pretreated with 0.3% hydrogen peroxide to block endogenous peroxidase, and then with reagents to block endogenous biotin (Biotin Blocking System, Dako, USA). The sections were incubated with rabbit anti-ß-galactosidase antibody (anti-ß-gal; Cappel, Durham, NC) for 30 minutes at room temperature, followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Dako, Tokyo, Japan), then colored with 3-amino-9-ethylcarbazole (AEC; Dako, Tokyo, Japan), or incubated with biotin-conjugated goat anti-rabbit IgG (Nichirei, Tokyo, Japan), and alkaline phosphatase-conjugated streptavidin (Dako, Tokyo, Japan), and then colored with fast blue BB. For confirming the cell-type specificity of the transgene-expressing cells, fast blue BB-stained trangenic brain specimens were double-stained with mouse monoclonal antibody (mAb) specific for neuron-specific-enolase (NSE) (Novocastra Lab. Ltd., Newcastle, UK), ß-tubulin isotipe III (Sigma, St. Louis, MO), MAP2 (Sigma), or with rabbit antibody specific for glial fibrillary acidic protein (GFAP) (Dako, Tokyo, Japan). For detection of MCMV-infected cells, infected brains were immunohistochemically stained using mouse mAb D5, specific for the MCMV early nuclear antigen,21 which is the product of e1 gene (M112–113).22

Intracerebral MCMV Inoculation of Neonatal Mice

Virus preparation of MCMV Smith strain was described previously.28 The titer of the purified virus stock was 4 x 108 plaque forming units (PFU)/ml. The intracerebral infection of neonatal mice with MCMV was done within 24 hours of their birth.29 The neonatal mice were outbred from individual transgenic founder mice, and half of the total neonates from a pregnant transgenic founder were inoculated with MCMV, while the other half were injected with Minimum Essential Medium (MEM) as a negative control. The viral stock was diluted with MEM to an appropriate titer (105 PFU/µl), and 105 PFU of virus was injected into the right side of the cerebral hemisphere through the cranial bone using a microsyringe. The negative inoculation control group was injected with the same volume of MEM in the same way. Positive cells were counted in the cerebral cortex of the coronal sections and the numbers were expressed per cortex area or per hippocampal area of each cerebral hemisphere. The data of three animals in each transgenic line were averaged.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Generation of MCMV e1-pro-lacZ Transgenic Mice

Transgenic mice that expressed the lacZ gene under the transcriptional control of the MCMV-e1-promoter (nucleotides - 1534 to + 38; Figure 1A ) were generated for analysis of the tissue-specific regulation of this promoter. Among the founder mice with transgene-integration detected by PCR, four independent transgenic lines were found to express the transgene by X-Gal staining. Southern blotting analysis of the four transgenic lines is shown in Figure 1B . The BamHI fragment (3.0 kb) from MCMV-e1-pro-lacZ was detected in these transgenic lines after digestion with BamHI (Figure 1B , lanes 6 to 9). The copy numbers of the transgene in the transgenic lines were determined by using NIH image software. The lines contained various transgene copy numbers: 10 copies in Tg-029 (lane 6), 32 copies in Tg-041 (lane 7), 3 copies in Tg-046 (lane 8), and 12 copies in Tg-033 (lane 9). The male founders were crossed with non-transgenic C57BL/6 mice, and transmitted the gene to ~ 50% of the offspring. These hemizygous males were mated with female C57BL/6 mice, and the offspring were used for further experiments.



View larger version (20K):
[in this window]
[in a new window]
  		Figure 1. Structure of the transgene, and Southern blot analysis. A: Construct used to generate MCMV-e1-pro-lacZ transgenic lines (transgene; 5.2 kb). The MCMV e1 (M112–113) promoter (MCMV-e1-pro) (nucleotides - 1534 to + 38) was inserted into the pnlacF vector,25 containing nuclear localization signal (N) and polyadenylation signals from the mouse protamine (mP1) gene. For the preparation of transgene, the vector was digested with KpnI and BglII. B: Southern blotting of the tail DNA from the four transgenic lines. Aliquots of 10 µg of tail DNA were digested with BamHI, electrophoresed in a 0.9% agarase gel, transferred to a nylon membranes, and probed with a 33P-labeled BamHI fragment (3.0 kb; A). Control lanes show increasing amounts: 0 copy (lane 1), 1 copy (lane 2), 5 copies (lane 3), 10 copies (lane 4), 20 copies (lane 5) of BamHI-digested mixtures of MCMV-e1-pro-lacZ with 10 µg of normal mouse tail DNA. Lane 6, Tg-029; lane 7, Tg-041; lane 8, Tg046; lane 9, Tg-033.

 
Expression of MCMV-e1-pro-lacZ in Transgenic Mice

Among four lines of founder mice bearing the MCMV-e1-pro-lacZ transgene, three lines (Tg-029, Tg-041, and Tg-046) were found to express the transgene as indicated by X-Gal staining of 4-week-old transgenic mice. In one line (Tg-033), expression of the transgene was not detected in normal conditions. However, the expression was detected by induction with MCMV infection (shown below). In all of the transgenic lines, expression of the transgene was restricted to the CNS (Figure 2) . X-gal-positive-regions were seen in the cerebral cortex, hippocampus, diencephalon, cerebellar cortex, brainstem, and ventral dorsal horn of the spinal cord (Figure 2) . Expression of ß-gal was also assayed quantitatively by the LightCycler RT-PCR. Almost no expression was found in organs other than the CNS in any of the transgenic lines (Figure 3A) . Although expression was weakly observed using LightCycler RT-PCR in the salivary glands, kidney, and muscles in Tg-029 lines, no positive band was observed in ordinary PCR (Figure 3B) . Furthermore, no positively stained cells were found in these organs by immunohistochemical staining using anti-ß-gal Ab.



View larger version (58K):
[in this window]
[in a new window]
  		Figure 2. ß-galactosidase expression in the CNS in 4-week-old transgenic lines. The sliced brains and spinal cords from three transgenic lines (Tg-029, Tg-041, Tg-046, and Tg-033) were stained for X-Gal. A: Coronal cerebral slices through frontal lobe. B: Coronal cerebral slices through the mammillary bodies. C: Sagittal slices of the brainstem and cerebellum. D: Spinal cords. In Tg-033, expression of the transgene was not detected in normal conditions.

 


View larger version (21K):
[in this window]
[in a new window]
  		Figure 3. Expression of ß-galactosidase of the organs from Tg-029 assayed quantitatively by the LightCycler RT-PCR. A: RNAs extracted from the various organs of Tg-029 mice, were reverse-transcribed into cDNA, then assayed by the LightCycler using the primers specific for ß-gal and for HPRT. Copy numbers were calculated with reference to standard sample. The copy numbers of ß-gal cDNA from organs were expressed as divided by those of mouse HPRT cDNA for normalization. Data were averages of three experiments. B: The same cDNAs were subjected to ordinary PCR using same primers. The PCR products were electrophoresed on 2% agarose gels.

 
Expression of MCMV-e1-pro-lacZ in the CNS

Immunohistochemical analysis was performed in the CNS of the 4-week-old transgenic mice using the anti-ß-gal Ab. Expression of the transgene was confined to subpopulation of neurons, as indicated by the morphology of cells and distribution of the expressed cells. Although the distribution was different in some degree among the transgenic lines, positively stained neurons were observed in the cerebral cortex, hippocampus, diencephalon, Purkinje cells in the cerebellar cortex, deep cerebellar nuclei, brainstem, and the spinal cord (Figure 4 , Table 1 ).



View larger version (148K):
[in this window]
[in a new window]
  		Figure 4. Immunohistochemical staining of expression of MCMV-e1-pro-lacZ in transgenic mice. The CNS tissues from a 4-week-old transgenic Tg-029 line were fixed in 4% PFA and embedded in paraffin. Deparaffinized sections were incubated with the anti-ß-galactosidase antibody (anti-ß-gal), followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG, and then colored with 3-amino-9-ethyl carbazole (AEC). A and B: Cerebral cortex. C and D: Hippocampus dentate gyrus (DG). E and F: Diencephalon. G and H: Cerebellar cortex. Purkinje cells (arrows). I: Brainstem. J: Spinal cord. Bars, 100 µm (A, C, E, G, I, and J); 30 µm (B, D, F, and H).

 

View this table:
[in this window]
[in a new window]
  		Table 1. Comparison of Expression of the MCMV e1-promoter-lacZ in the CNS in Transgenic Mice

 
In the cerebral cortex of the Tg-029 transgenic line, ß-gal-positive neurons were evenly distributed throughout the cerebral layer (Figure 4, A and B) . In the limbic system, ß-gal-positive neurons were observed in the hippocampus and amygdala. In the hippocampus, the positive neurons were observed in the CA1 region in all of the transgenic lines (Figure 4, C and D) . In the amygdala, positive neurons were observed only in the Tg-029 line (not shown). No expression was observed in the dentate gyrus in any of the trangenic lines (Table 1) . In diencephalon, ß-gal-positive cells were observed in the thalamus (Figure 3, E and F) and hypothalamus (not shown). In the cerebellum, expression of the trangene was observed in some Purkinje cells but not in granular cells (Figure 4, G and H) . In the brainstem, positive cells were scattered in midbrain, pons, and medulla oblongata (Figure 4I) . In the spinal cord, positive cells were observed in the dorsal and ventral horns (Figure 4J) . A summary of the distribution of the transgene-expressing neurons in the three transgenic lines (Tg-029, Tg-041, and Tg-046) in the CNS is shown in Table 1 .

Combined Staining for ß-Galactosidase Activity and Immunohistochemical Staining of Neural Cell Markers

To further confirm that the MCMV-e1-pro-lacZ-expressing cells are neuronal cells, the transgene-expressing cells were double-stained immunohistochemically for neuronal and glial markers. Although neurons were not always stained with any antibody to a single neuronal marker, most of ß-gal-expressing cells were double-stained with anti-NSE mAb (Figure 5A) , anti-ß-tubulin mAb (Figure 5B) , or anti-MAP2 mAb (Figure 5C) , but not double-stained with anti-GFAP Ab (Figure 5D) . In addition to the evidence based on the morphology and distribution of ß-gal-positive cells, these results further confirmed that the activation of the MCMV-e1-promoter in our transgenic lines was neuron-specific in the CNS.



View larger version (83K):
[in this window]
[in a new window]
  		Figure 5. Immunohistochemical double staining of ß-galactosidase and neural markers. To confirm that ß-gal-positive cells are neuronal cells, the cerebral cortex of a 4-week-old Tg-029 mouse was double-stained using anti-ß-gal Ab and anti-neuron-specific enolase (NSE) Ab (A), anti-ß-tubulin (B), anti-MAP2 (C), or anti-GFAP Ab (D). The brain that had been incubated with anti-ß-gal Ab was colored with fast blue BB (blue), then incubated with antibodies specific to neural markers and colored with AEC (red). Bars, 30 µm.

 
Developmental Alterations of the Expression of MCMV-e1-pro-lacZ

To examine the expression of the transgene during development, brains of transgenic lines from E15.5 to P28 were examined immunohistochemically using anti-ß-gal Ab. Positive cells were identified starting at postnatal stages except in one line (Tg-029) in which positive cells were already detected on E18.5 in the mesencephalon (not shown). The expression pattern of the ß-gal-positive cells was basically the same in all of the transgenic lines: the number of ß-gal-positive cells gradually increased and the distribution spread as development proceeded. In the Tg-029 line, a small number of ß-gal-expressing cells were first detected on E18.5 in the cortex (Figure 6A) . In the postnatal phase, remarkable staining of positive cells was observed around the upper cerebral layer (Figure 6, B and C) . The number of the ß-gal-expressing cells increased and the distribution spread to all of the cortical layers (Figure 6D) .



View larger version (103K):
[in this window]
[in a new window]
  		Figure 6. Alternation of activation of the MCMV-e1-promoter during the brain development. Expression of the transgene was examined immunohistochemically using anti-ß-gal Ab in Tg-029 line at E18.5 (A and E), P3 (B and F), P7 (C and G), and P28 (D and H). In the cerebral cortex (A–D) and hippocampus (E–H), positive cells gradually increase and the distribution expanded as the growth proceeded. Bars, 100 µm (A–D), 200 µm (E–H).

 
In the hippocampus, ß-gal-positive cells were not detected on E18.5 (Figure 6E) , and positive cells were first observed mainly in the median CA1 region of the P3 brains (Figure 6F) . As the brain development proceeded, the number of the positive cells increased and the positive cells spread toward the CA3 region (Figure 6, G and H) .

In the cerebellum, positive cells were first observed on E18.5 in the Tg-029 line, the expression was clearly detected in Purkinje cells and in the deep cerebellar nuclei from the postnatal stage in the Tg-029 and Tg-041 lines (not shown). In the cerebellum, the number of transgene-expressing cells did not increase markedly as development proceeded.

Enhancement of MCMV-e1-pro-lacZ Expression by Intracerebral Infection with MCMV

As the MCMV early gene e1 (M112–113) has been reported to be transactivated by IE gene expression,24 as is the HCMV UL112–113 gene,30 we investigated the effect of MCMV infection on the activation of the e1 promoter in the transgenic lines.

Expression of the transgene in the Tg-033 line was not detected in uninfected mice by immunohistochemical staining (Figure 7, A and E) . However, when the brains were infected with MCMV within 24 hours after birth, ß-gal-positive cells appeared in the cerebral cortex (Figure 7B , arrows, Figure 8 Tg-033, B) and in the hippocampus (Figure 7F , Figure 8 ) 6 days after infection. These ß-gal-positive cells were neurons as in the other transgenic lines described above. Many virus-infected cells were observed in the same regions in the adjacent sections stained with mAb D5, which is specific for the MCMV early nuclear antigen, which is an e1 gene product (Figure 7, C and G , Figure 8 , Tg-033, D). Another adjacent section stained with anti-ß-gal Ab was double-stained with mAb D5 (Figure 7, D, H , arrows, Figure 8 , Tg-033, C). The ß-gal-expression was not always induced in virus-infected cells (Figure 7, D, H , arrowheads). However, most of ß-gal-positive cells were virus-infected cells but not uninfected cells (Figure 7, D and H , Figure 8 , compare Tg-033 B and C). The virus antigen was sometimes seen in the part of ß-gal-positive nuclei as a dotted or punctate pattern as described previously,21 or seen in HCMV-infected cells stained with the antibody specific for the UL112–113 gene product.23 Although a neuron singly positive for ß-gal was rarely seen in nucleus (Figure 7, D, H, *) , it is possible that the viral antigen may not be seen in a section of the nucleus. In the Tg-046 line, ß-gal-staining neurons were observed in the deep layer of the cortex in uninfected mice (Table 1) . The number of the ß-gal-positive neurons was significantly increased by MCMV infection in the cortex and hippocampus (Figure 8 Tg-046, A and B). In other transgenic lines (Tg-029 and Tg-041), no distinct induction of the ß-gal-positive cells was detected in the cortex but induction was observed in the hippocampus after MCMV infection (Figure 8 , Tg-029, A and B). The induction was somewhat different between cortex and hippocampus and was difficult to estimate in the brains of the Tg lines where the diffuse expression of the transgene had already occurred in uninfected state.



View larger version (106K):
[in this window]
[in a new window]
  		Figure 7. Induction of activation of the MCMV-e1-promoter in the Tg-033 brain by MCMV infection. Intracerebral injection of the transgenic mice with MCMV (105 PFU) was performed within 24 hours after their birth, and the brains were examined at P7. Intracerebral injection of the same litter of the transgenic mice with MEM was also performed in the same manner for uninfected control. A–D: Cerebral cortex. E–H: Hippocampus. The brain sections were immunohistochemically stained using anti-ß-gal Ab, colored with AEC (red) (A and E, uninfected; B and F, infected; arrows, ß-gal-positive cells). C and G: Adjacent section of B and F were stained with mAb D5, specific to the MCMV early antigen, colored with fast blue BB (blue). D and H: The ß-gal-positive cells induced by MCMV infection were (red) were double-stained with the rat mAb D5 (blue). Arrows, double-positive cells. Arrowheads, ß-gal-negative-infected cells. *, cells singly positive for ß-gal. Bars, 100 µm (A–C and E–G); D and H, 30 µm.

 


View larger version (17K):
[in this window]
[in a new window]
  		Figure 8. Quantitative comparison of ß-gal-expressed neurons between uninfected and MCMV-infected cerebral cortex and hippocampus in the transgenic lines (Tg-029, Tg-046, and Tg-033). Transgenic mouse brains from same littermate were injected with MEM (A) and with MCMV (105 PFU) (B) in the same manner as Figure 7 . C: ß-gal-expressed neurons double-stained with mAb D5, specific for MCMV early nuclear antigen. D: Virus-infected cells stained with mAb D5. Positive cell numbers were expressed per cortex area or hippocampus of each cerebral hemisphere. The data of three animals in each transgenic line were averaged. *, P < 0.05 (Student’s t-test).

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
The brain is the main target in congenital cytomegalovirus (CMV) infection2-4 and immunocompromised patients, especially AIDS patients.7 However, no definite evidence that CMV has a special affinity for the CNS has been published. We previously reported that the early gene e1 (M112–113) product has a tendency to be retained in neurons of MCMV-infected mouse brains,16 especially in prolonged infection.20

Interestingly, the present study showed that activity of the MCMV early gene e1 promoter was restricted to the CNS in transgenic mice. Furthermore, the activation was observed only in neurons. This fact suggests that neurons of the CNS in vivo contain factors that drive the promoter for expression of the MCMV early gene in the absence of the viral immediate-early (IE) gene products. The MCMV early gene e1 (M112–113)22 was reported to be the counterpart of UL112–113 of HCMV30,31 which produces a family of four differentially spliced transcripts.32 The early gene is known to be stimulated by the HCMV IE gene products, which act as transactivators.30,32,33 Bühler et al24 reported that expression of the MCMV early gene was also induced by the MCMV IE proteins. It is known that the cascade of expression of the early genes of CMV is induced by the IE gene products together with host cellular factors.14,32 The present study suggests that the MCMV early promoter can be activated in neurons of the CNS by some factors substituting for the IE products. Mocarski et al34 reported that a deletion mutant of HCMV IE1 replicated under high infective titer conditions, and they suggested that virion transactivators compensated for the lack of IE1. Therefore, it may not be necessary for the viral IE genes to be expressed for the activation of viral early gene expression in certain situations.

Neuron-specific activation of host gene promoters in transgenic mice, including the neuron-specific enolase (NSE) gene,35 dopamine ß-hydroxylase (DBH) gene,25,36 and the ß2-subunit of the neuronal nicotinic acetylcholine receptor gene37 has been reported. Neuron-specific activation in transgenic mice has also been observed for viral genes such as HSV-1 IE.38,39 Common features of activation of neuron-specific genes in transgenic mice were as follows: the activation was observed in subpopulation of neurons but not all neurons, and was linked to neuronal maturation, although the onset of activation was observed from the embryonic stage. The activation pattern of the MCMV-e1-promoter seen in the present study was basically similar to these features. Although there was some variability in the number and distribution of the activated cells among various transgenic lines, activation of the transgene was observed in subpopulation of neurons in ubiquitous sites of the CNS, like activation of the NSE promoter.35 However, in the MCMV-e1-promoter transgenic mice, expression in the granular cells of the cerebellum was not activated, and no activation was observed in organs other than the CNS, including the testes, where the NSE promoter was activated.35

The transgene-expressing neurons were distributed in some layers of the cerebral cortex, part of the hippocampus, diencephalon, brainstem, Purkinje cells of the cerebellum, and spinal cord. Although the transgene-expressing neurons were observed in some degree in the embryonic stage in one of transgenic lines, activation of the promoter became more extensive postnatally in neurons of the cerebral cortex and hippocampus as development and maturation of the neurons proceeded. The number of activated cells was not correlated with the transgene copy number, in agreement with findings reported previously.35,38 In contrast to the activation to the MCMV IE promoter in transgenic mice,19 activation of the e1-promoter was not observed in neural progenitor cells during brain development.

In the present study, we showed that the number and extent of the activated neurons were increased in the less expressed transgenic lines by intracerebral infection with MCMV. It is possible that in vivo the IE gene products expressed by MCMV infection activate the e1-promoter, as observed in vitro.24 Expression of HCMV early UL112–113 was also reported to be stimulated at least 10- to 20-fold by IE 86 protein.32,40 However, the enhancement of the activation of the early promoter induced by infection was not as marked in the transgenic mice as seen in vitro experiments. Furthermore, induction of the activation did not always occur in all of the infected cells, although the activation seemed to restrict to the infected neurons, suggesting that induction of activation of the e1-promoter occurs in virus-infected cells but not induced by extracellular factors alone in the virus infected brain. Expression of the e1-promoter is different between in vivo and in vitro. This may be because the early gene is chromosomally located in vivo, or because the infection of neurons is less efficient than in vitro infection. Alternatively, some factors expressed in vivo may suppress the activation of the MCMV-e1-promoter.

The present evidence that activation of the MCMV-e1-promoter is restricted to neurons in transgenic mice may account, at least in part, for the special affinity of CMV for the CNS. Furthermore, neuron-specific expression of the e1 gene may cause neuronal disorders in congenital infection, and in immunocompromised patients, especially those with AIDS.7 In the acute phase of infection of the CNS, lytic infection of glial cells may be predominant.16,17 In human autopsy cases, glial cells in the periventricular zone show special susceptibility to CMV infection, sometimes with calcification.2,3,15 These infected cells show strong expression of the IE antigen and late antigen, and an increased level of viral DNA.16 In accordance with those findings, we reported that the MCMV IE promoter directs glial-specific expression in transgenic mice.18,19 In contrast, in the chronic MCMV infection of the developing mouse brain, expression of the early nuclear antigen, corresponding to the M112–113 products, was diffusely distributed in neurons of the cerebral cortex and the hippocampus.16,20 Since the viral DNA was not increased in these early antigen-expressing neurons, CMV may have persistently infected these neurons. It is suggested that evasion of the innate immune responses by MCMV-infected neurons may be an important factor in supporting the viral persistence in the developing brain.29

It has been reported that neurotropic virus infection in the CNS tends to become persistent infection in neurons.41 CMV IE promoters of both HCMV42 and MCMV13 appear to be not well-activated in neurons when compared to glial cells. Therefore, acute phase of CMV infection of the brain, in which lytic infection of glial cells is predominant, may convert to the chronic phase of infection in which persistent infection of neurons is predominant.29 Activation of the early gene e1 may be important for the transition of neurons to persistent infection. Although HCMV UL112–113 was reported to play a role in viral DNA replication in permissive cells,43 the early gene E1 product in neurons may have other functions, and neuronal dysfunction or neuronal cell death may be induced by accumulation of the product in neurons. The role of the early gene E1 product in neurons in the pathogenesis of neuronal disorders in congenital CMV infection and in immunocompromised patients with AIDS remains to be elucidated.

In conclusion, using transgenic mice, we obtained here definite evidence that activation of the MCMV early e1 gene promoter was tightly restricted to subpopulation of neurons in the CNS. This fact suggests that neurons contain specific factors that drive the viral early gene and that this neuron-specific activation may be associated with persistent infection in neurons, and may cause the neuronal disorders in congenital CMV infection.


   Acknowledgements
 
We thank Mr. Masaaki Kaneta, Miss Mitsue Kawashima, and Mrs. Hiromi Suzuki for their excellent technical assistance. We also thank Dr. Richard D. Palmiter, University of Washington, Seattle, WA, for providing the pnlacF vector.


   Footnotes
 
Address reprint requests to Dr. Yoshihiro Tsutsui, Second Department of Pathology, Hamamatsu University School of Medicine, 1–20-1 Handayama, Hamamatsu 431–31-92, Japan. E-mail: ytsutsui{at}hama-med.ac.jp

Supported in part by grant 12470054 from the Ministry of Education, Science and Technology, Japan.

Accepted for publication April 29, 2003.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Weller TH: The cytomegalovirus: ubiquitous agents with protean clinical manifestations. N Engl J Med 1971, 285:203-214
  2. Becroft DMO: Prenatal cytomegalovirus infection: epidemiology, pathology, and pathogenesis. Perspect Pediatr Pathol 1981, 6:203-241[Medline]
  3. Stagno S, Pass RF, Cloud G, Bright WJ, Henderson RE, Walton PD, Veren DA, Page F, Alford CA: Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outocome. JAMA 1986, 256:1904-1908[Abstract]
  4. Ho M: Congenital and perinatal human cytomegalovirus infection. Ho M eds. Cytomegalovirus: Biology and Infection. 1991:pp 205-227 Plenum New York
  5. Pass RF, Stagno S, Myers GJ, Alford CA: Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 1980, 66:758-762[Abstract/Free Full Text]
  6. Conboy TJ, Pass RF, Stagno S, Brtt WJ, Alford CA, MacFarland CE, Boll TJ: Intellectual development in school-aged children with asymptomatic congenital cytomegalovirus infection. Pediatrics 1986, 77:801-806[Abstract/Free Full Text]
  7. Cinque P, Marenzi R, Ceresa D: Cytomegalovirus infections of the nervous system. Intervirology 1997, 40:85-97[Medline]
  8. Morgello S, Cho ES, Nielsen S, Devinsky O, Petito CK: Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of literature. Hum Pathol 1987, 18:289-297[Medline]
  9. Wiley CA, Nelson JA: Role of human immunodeficinecy virus and cytomegalovirus in AIDS encephalitis. Am J Pathol 1988, 133:73-81[Abstract]
  10. Setinek U, Wondrucsh E, Jellinger K, Steuer A, Drlicek M, Grisold W, Lintner F: Cytomegalovirus infection of the brain in AIDS: a clinicopathological study. Acta Neuropathol 1995, 90:511-515[Medline]
  11. Tsutsui Y, Kashiwai A, Kawamura N, Kadota C: Microphthalmia and cerebral atrophy induced in mouse embryos by infection with murine cytomegalovirus in midgestation. Am J Pathol 1993, 143:804-812[Abstract]
  12. Tsutsui Y: Developmental disorders of the mouse brain induced by murine cytomegalovirus: animal models for congenital cytomegalovirus infection. Pathol Int 1995, 45:91-102[Medline]
  13. van Den Pol AN, Mocarski E, Saederup N, Vieira J, Meier TJ: Cytomegalovirus cell tropism, replication, and gene transfer in brain. J Neurosci 1999, 19:10948-10965[Abstract/Free Full Text]
  14. Mocarski ES: Cytomegalovirus and their replication. Fiels BN Knipe DM Howley PM eds. Virology, ed 3 1996:pp 2447-2492 Lippincott-Raven Philadelphia
  15. Perlman JM, Argyle C: Lethal cytomegalovirus infection in preterm infants; clinical, radiological, and neuropathological findings. Ann Neurol 1992, 31:64-68[Medline]
  16. Shinmura Y, Aiba-Masago S, Kosugi I, Li RY, Baba S, Tsutsui Y: Differential expression of the immediate-early and early antigens in neuronal and glial cells of developing mouse brains infected with murine cytomegalovirus. Am J Pathol 1997, 151:1331-1340[Abstract]
  17. Li RY, Tsutsui Y: Growth retardation and microcephaly induced in mice by placental infection with murine cytomegalovirus. Teratology 2000, 62:79-85[Medline]
  18. Aiba-Masago S, Baba S, Li RY, Shinmura Y, Kosugi I, Arai Y, Nishimura M, Tsutsui Y: Murine cytomegalovirus immediate-early promoter directs astrocyte-specific expression in transgenic mice. Am J Pathol 1999, 154:735-743[Abstract/Free Full Text]
  19. Li RY, Baba S, Kosugi I, Arai Y, Kawasaki H, Shinmura Y, Sakakibara S, Okano H, Tsutsui Y: Activation of murine cytomegalovirus immediate-early promoter in cerebral ventricular zone and glial progenitor cells in transgenic mice. Glia 2001, 35:41-52[Medline]
  20. Tsutsui Y, Kashiwai A, Kawamura N, Aiba-Masago S, Kosugi I: Prolonged infection of mouse brain neurons with murine cytomegalovirus after pre- and perinatal infection. Arch Virol 1995, 140:1725-1736[Medline]
  21. Tsutsui Y, Naruse I: Murine cytomegalovirus infection of cultured mouse embryos. Am J Pathol 1987, 127:262-270[Abstract]
  22. Rawlinson WD, Farrell HE, Barrell BG: Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 1996, 70:8833-8849[Abstract]
  23. Iwayama S, Yamamoto T, Furuya T, Kobayashi R, Ikuta K, Hirai K: Intracellular localization and DNA-binding phosphoprotein in human fibroblasts infected with human cytomegalovirus (Town strain). J Gen Virol 1994, 75:3309-3318[Abstract/Free Full Text]
  24. Bühler B, Keil GM, Weiland F, Koszinowski UH: Characterization of the murine cytomegalovirus early transcription unit e1 that is induced by immediate-early proteins. J Virol 1990, 64:1907-1919[Abstract/Free Full Text]
  25. Mercer EH, Hoyle GW, Kapur RP, Brinster RL, Palmiter RD: The dopamine ß-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 1991, 7:703-716[Medline]
  26. Hogan B, Costantini F, Lacy E: Manipulating the Mouse Embryo: A Laboratory Manual. 1986:pp 153-186 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
  27. Schaade L, Kockelkorn P, Ritter K, Kleines M: Detection of cytomegaloirus DNA in human specimens by LightCycler PCR. J Virol 2000, 38:4006-4009
  28. Kosugi I, Shinmura Y, Li R-Y, Aiba-Masago S, Baba S, Miura K, Tsutsui Y: Murine cytomegalovirus induces apoptosis in non-infected cells of the developing mouse brain and blocks apoptosis in primary neuronal culture. Acta Neuropathol 1998, 96:239-247[Medline]
  29. Kosugi I, Kawasaki H, Arai Y, Tsutsui Y: Innate immune responses to cytomegalovirus infection in the developing mouse brain and their evasion by virus-infected neuron. Am J Pathol 2002, 161:919-928[Abstract/Free Full Text]
  30. Staprans SI, Rabert DK, Spector DH: Identification of sequence requirements and trans-acting functions necessary for regulated expression of a human cytomegalovirus early gene. J Virol 1988, 62:3463-3473[Abstract/Free Full Text]
  31. Wright DA, Staprans SI, Spector DH: Four phosphoproteins with common amino termini are encoded by human cytomegalovirus AD 169. J Virol 1988, 62:331-340[Abstract/Free Full Text]
  32. Spector DH: Activation and regulation of human cytomegalovirus early genes. Intervirology 1996, 39:361-377[Medline]
  33. Klucher KM, Rabert DK, Spector DH: Sequences in the human cytomegalovirus 2.7-kilobase RNA promoter which mediate its regulation as an early gene. J Virol 1989, 63:5334-5343[Abstract/Free Full Text]
  34. Mocarski ES, Kemble GW, Lyle JM, Greaves RF: A deletion mutant in the human cytomegalovirus gene encoding IE1491aa is replication defective due to a failure in autoregulation. Proc Natl Acad Sci USA 1996, 93:11321-11326[Abstract/Free Full Text]
  35. Forss-Petter S, Danielson PE, Catsicas S, Battenberg E, Price J, Nerenberg M, Sutcliffe JG: Transgenic mice expressing ß-galactosidase in mature neuron under neuron-specific enolase promoter control. Neuron 1990, 5:187-197[Medline]
  36. Kapur RP, Hoyle GW, Mercer EH, Brinster RL, Palmiter RD: Some neuronal cell populations express human dopamine ß-hydroxylase-lacZ transgenes transiently during embryonic development. Neuron 1991, 7:717-727[Medline]
  37. Bessis A, Salmon AM, Zoli M, Le Novere N, Picciotto M, Changeux JP: Promoter elements conferring neuron-specific expression of the ß2-subunit of the neuronal nicotinic acetylcholine receptor studied in vitro and in transgenic mice. Neuroscience 1995, 69:807-819[Medline]
  38. Mitchell WJ: Neurons differentially control expression of a herpes simplex virus type 1 immediate-early promoter in transgenic mice. J Virol 1995, 69:7942-7950[Abstract]
  39. Loiacono CM, Myers R, Mitchell WJ: Neurons differentially activate the herpes simplex virus type 1 immediate-early gene ICP0 and ICP27 promoters in transgenic mice. J Virol 2002, :2449-2459
  40. Klucher KM, Sommer M, Kadonaga JT, Spector DH: In vivo and in vitro analysis of transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins. Mol Cell Biol 1993, 13:1238-1250[Abstract/Free Full Text]
  41. Lipton HL, Gilden DH: Viral diseases of the nervous system: persistent infection. Nathanson N eds. Viral Pathogenesis. 1997:pp 855-869 Lippincott-Raven Philadelphia
  42. Shering AF, Bain D, Stewart K, Epstein AL, Castro MG, Wilkinson GW, Lowenstein PR: Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J Gene Virol 1997, 78:445-459[Abstract]
  43. Pari GS, Anders DG: Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent replication. J Virol 1993, 67:6979-6988[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arai, Y.
Right arrow Articles by Tsutsui, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arai, Y.
Right arrow Articles by Tsutsui, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS